A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
Completed · Phase 1
Conditions studied: Cancer
In brief
This is a Phase 1 study during which patients with advanced HER2+ solid malignancies or HER2+ metastatic breast cancer will receive investigational study drug ARRY-380. This study has 2 parts. In the first part, patients with advanced HER2+ solid malignancies, who have already received at least one previous standard therapy, will receive increasing doses of study drug in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 30 patients from the US will be enrolled in Part 1 (Completed). In the second part of this study, patients with HER2+ metastatic breast cancer, who have already received at least one previous standard therapy, will receive the best dose of study drug determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 20 patients from the US will be enrolled in Part 2 (Active, not recruiting).
Key facts
- Study ID
- NCT00650572
- Run by
- Seagen Inc.
- People needed
- 50
- Starts
- 2008-05-01
- Expected to finish
- 2013-03-01
- Last updated by the study team
- 2020-05-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The University of Colorado Cancer Center — Aurora, Colorado, United States
- The University of Texas, MD Anderson Cancer Center — Houston, Texas, United States
- British Columbia Cancer Agency — Vancouver, British Columbia, Canada
- Cancer Centre of Southeastern Ontario at Kingston General Hospital — Kingston, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.